Eli Lilly and Co has agreed to pay $62 million to settle claims that it improperly marketed its top-selling Zyprexa schizophrenia drug to patients who were not approved users, the company said on Tuesday. Reuters Health Information
This comprehensive review finds a wide volume and breadth of work focused on the development of frameworks for performance and quality improvement purposes. International Journal for Quality in Health Care
A review concludes that nearly 20% of completed trials of drug treatment for acute stroke are not ultimately published, but experts debate the relevance of this finding. Medscape Medical News